Phase I and II studies with hexitol derivatives, formyl-leurosine and ftorafur.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004852:Epoxy Compounds / Q000009:adverse effects / Q000627:therapeutic use; D004376:Galactitol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008936:Mitolactol / Q000009:adverse effects / Q000627:therapeutic use; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use; D014748:Vinca Alkaloids / Q000009:adverse effects / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004852:Epoxy Compounds; D014748:Vinca Alkaloids; D004376:Galactitol; D005641:Tegafur; D008936:Mitolactol